2023
222-OR: Metformin Reduces Fasting Glycemia in Well-Controlled Type 2 Diabetes by Promoting Aerobic Glycolysis Independent of Decreasing Endogenous Glucose Production
SARABHAI T, LAMOIA T, FRIESL S, JONUSCHEIT M, PETERSEN K, SHULMAN G, RODEN M. 222-OR: Metformin Reduces Fasting Glycemia in Well-Controlled Type 2 Diabetes by Promoting Aerobic Glycolysis Independent of Decreasing Endogenous Glucose Production. Diabetes 2023, 72 DOI: 10.2337/db23-222-or.Peer-Reviewed Original ResearchEndogenous glucose productionRates of EGPType 2 diabetesHepatic ATP contentMetformin treatmentGlucose clearanceNovo NordiskGlucose productionGlycogen contentGlucose-lowering effectHepatic TAG contentLactate productionBlood glucose levelsPlasma glucose concentrationPeripheral glucose clearanceHepatic glycogen contentATP contentAdvisory PanelFortress BiotechMetformin-induced inhibitionGlycemic controlDohme Corp.Hepatic triglyceridesMitochondrial electron transport chain activityGlucose levels
2022
195-OR: A Novel 13C5 Glutamine Tracer Method (Q Flux) Reveals a Key Role of Succinyl CoA Anaplerosis in Promoting Increased Rates of Hepatic Gluconeogenesis during Hyperglucagonemia
HUBBARD B, SHULMAN G. 195-OR: A Novel 13C5 Glutamine Tracer Method (Q Flux) Reveals a Key Role of Succinyl CoA Anaplerosis in Promoting Increased Rates of Hepatic Gluconeogenesis during Hyperglucagonemia. Diabetes 2022, 71 DOI: 10.2337/db22-195-or.Peer-Reviewed Original ResearchSuccinyl CoAEndogenous glucose productionMetabolic flux analysis methodHepatic gluconeogenesisAnaplerotic pathwaysUnexpected roleHD animalsType 2 diabetes mellitusMale Sprague-Dawley ratsHigh-dose glucagonLow-dose glucagonNovel targetSprague-Dawley ratsRespective substratesPlasma glucose concentrationGlutamine122-LB: Effect of Dapagliflozin on Mitochondrial Metabolism and Cardiac Function in the Failing Heart
GOEDEKE L, MA Y, ZHANG J, GUERRERA N, WU X, ZHANG D, KAHN M, ZHANG X, YOUNG L, SHULMAN G. 122-LB: Effect of Dapagliflozin on Mitochondrial Metabolism and Cardiac Function in the Failing Heart. Diabetes 2022, 71 DOI: 10.2337/db22-122-lb.Peer-Reviewed Original ResearchDAPA treatmentLV ejection fractionEjection fractionHeart failureMI ratsCardiac outputMyocardial infarctionCardiac functionLeft ventricularEffect of dapagliflozinMale Sprague-DawleyPlasma glucose concentrationMalonyl-CoA contentMitochondrial oxidationKetone availabilityΒOHB levelsVehicle treatmentPermanent ligationSGLT2 inhibitionSGLT2 inhibitorsCardioprotective effectsCoronary arteryAcetyl-CoA contentFailing HeartMitochondrial metabolismMetformin, phenformin, and galegine inhibit complex IV activity and reduce glycerol-derived gluconeogenesis
LaMoia TE, Butrico GM, Kalpage HA, Goedeke L, Hubbard BT, Vatner DF, Gaspar RC, Zhang XM, Cline GW, Nakahara K, Woo S, Shimada A, Hüttemann M, Shulman GI. Metformin, phenformin, and galegine inhibit complex IV activity and reduce glycerol-derived gluconeogenesis. Proceedings Of The National Academy Of Sciences Of The United States Of America 2022, 119: e2122287119. PMID: 35238637, PMCID: PMC8916010, DOI: 10.1073/pnas.2122287119.Peer-Reviewed Original ResearchConceptsGlucose-lowering effectPlasma glucose concentrationComplex I activityHepatic gluconeogenesisType 2 diabetes mellitusGlucose concentrationGlycerol-3-phosphate dehydrogenase activityI activityDiabetes mellitusSelective inhibitionMetforminInhibitionRelevant concentrationsGluconeogenesisPhenforminVivoMost studiesDehydrogenase activityGalegineMellitus
2020
Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks
Perry RJ, Shulman GI. Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks. Journal Of Biological Chemistry 2020, 295: 14379-14390. PMID: 32796035, PMCID: PMC7573269, DOI: 10.1074/jbc.rev120.008387.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSodium-glucose cotransporter 2SGLT2 inhibitorsEuglycemic ketoacidosisGlucose reabsorptionTherapeutic promiseSGLT2 inhibitor therapyLower plasma glucose concentrationsModest weight lossGlucose-lowering agentsRenal glucose reabsorptionType 2 diabetesType 1 diabetesPlasma glucose concentrationGlucose concentrationBlood glucose concentrationHeart failureInhibitor therapyAtrial fibrillationCardiovascular diseaseCotransporter 2Preclinical studiesHealthy personsClinical utilityDiabetes managementProximal tubules
2018
Effect of a Controlled-Release Mitochondrial Protonophore (CRMP) on Healthspan and Lifespan in Mice
GOEDEKE L, CAMPOREZ J, NASIRI A, WANG Y, ZHANG X, SHULMAN G. Effect of a Controlled-Release Mitochondrial Protonophore (CRMP) on Healthspan and Lifespan in Mice. Diabetes 2018, 67 DOI: 10.2337/db18-123-lb.Peer-Reviewed Original ResearchControlled-release mitochondrial protonophoreCRMP treatmentHepatic steatosisDiet-induced rodent modelWhole body insulin responsivenessInflammation/fibrosisMale C57BL/6J miceWhole-body energy expenditureHyperinsulinemic-euglycemic clampHigh-fat dietType 2 diabetesGlucose infusion rateMitochondrial protonophorePlasma glucose concentrationWide therapeutic indexStrict dietary regimeSecond-generation compoundsTransaminase levelsFatty liverLiver triglyceridesInsulin resistanceAge-related diseasesC57BL/6J miceHepatic triglyceridesFood intake
1998
Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus
Inzucchi S, Maggs D, Spollett G, Page S, Rife F, Walton V, Shulman G. Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus. New England Journal Of Medicine 1998, 338: 867-873. PMID: 9516221, DOI: 10.1056/nejm199803263381303.Peer-Reviewed Original ResearchConceptsEndogenous glucose productionPlasma glucose concentrationPostprandial plasma glucose concentrationsPeripheral glucose disposalType 2 diabetesMetformin therapyTroglitazone therapyGlucose disposalGlucose productionHemoglobin valuesGlucose concentrationType II diabetes mellitusAdditive beneficial effectsSingle-drug therapyDiabetes mellitusGlycemic controlCombination therapyPoor responseMetabolic effectsPhysiologic effectsMetforminPatientsTherapyTroglitazoneBeneficial effects
1995
Contribution of Hepatic Glycogenolysis to Glucose Production in Humans in Response to a Physiological Increase in Plasma Glucagon Concentration
Magnusson I, Rothman D, Gerard D, Katz L, Shulman G. Contribution of Hepatic Glycogenolysis to Glucose Production in Humans in Response to a Physiological Increase in Plasma Glucagon Concentration. Diabetes 1995, 44: 185-189. PMID: 7859939, DOI: 10.2337/diab.44.2.185.Peer-Reviewed Original ResearchConceptsNet hepatic glycogenolysisLiver glycogen concentrationPlasma glucagon concentrationsHepatic glycogenolysisGlucagon concentrationsGlycogen concentrationLiver volumeGlucose productionPlasma glucose concentrationOverall glucose productionTwo-compartment modelHealthy subjectsPhysiological incrementsPhysiological increaseGlucose appearanceSame time periodMagnetic resonance imagesGlucose kineticsBaseline RaInfusionGlycogenolysisGlucose concentrationResonance imagesMumol
1980
Effect of hyperglycemia independent of changes in insulin or glucagon on lipolysis in the conscious dog
Shulman G, Williams P, Liljenquist J, Lacy W, Keller U, Cherrington A. Effect of hyperglycemia independent of changes in insulin or glucagon on lipolysis in the conscious dog. Metabolism 1980, 29: 317-320. PMID: 6103495, DOI: 10.1016/0026-0495(80)90004-9.Peer-Reviewed Original ResearchConceptsArterial plasma glucose concentrationDirect antilipolytic effectHepatic glycerol uptakeFree fatty acid concentrationsInfusion of somatostatinContinuous glucose infusionPlasma glucose concentrationBlood glycerol levelsHyperglycemia independentConscious dogsBlood glycerolFatty acid concentrationsPancreatic hormonesAntilipolytic effectGlucose infusionBasal levelsSignificant decreaseGlycerol levelsGlucose concentrationHyperglycemiaInfusionGlucagonInsulinFractional extraction
1978
Glucose Disposal during Insulinopenia in Somatostatin-Treated Dogs
Shulman G, Liljenquist J, Williams P, Lacy W, Cherrington A. Glucose Disposal during Insulinopenia in Somatostatin-Treated Dogs. Journal Of Clinical Investigation 1978, 62: 487-491. PMID: 670404, PMCID: PMC371787, DOI: 10.1172/jci109150.Peer-Reviewed Original ResearchConceptsNet hepatic glucose uptakeHepatic glucose productionHepatic glucose uptakeGlucagon secretionHepatic glucose storageBasal insulinGlucagon levelsGlucose storageNet hepatic glucose productionGlucose productionGlucose uptakeAbility of hyperglycemiaPancreatic hormone releasePlasma glucagon concentrationsPlasma glucagon levelsInduction of hyperglycemiaPlasma glucose levelsPlasma glucose concentrationHepatic glucose balanceIntraportal insulinGlucagon concentrationsConscious dogsSomatostatin inhibitionGlucagon infusionGlucose disposal